---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-25-000051"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:10:39.315868+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q2 revenue up 2% to $652M; completes Stilla acquisition

## Summary
- Q2 2025 revenue $651.6M (+2.1% YoY); GAAP net income $317.8M vs loss $2,165.5M (prior year included Sartorius losses).
- Non-GAAP EPS $2.61 vs $3.11; non-GAAP operating income $88.6M vs $106.9M, reflecting margin compression.
- GAAP gross margin 53.0% vs 55.6%; non-GAAP gross margin 53.7% vs 56.4%, down on product mix and costs.
- Completed acquisition of Stilla Technologies, expanding digital PCR portfolio with QX Continuum and QX700 systems.

## SEC filing metadata
- accession: 0000012208-25-000051
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220825000051/0000012208-25-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220825000051/bio-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-25-000051
- JSON: https://secwatch.observer/filing/0000012208-25-000051.json
- Plain text: https://secwatch.observer/filing/0000012208-25-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.